Overview

A Pharmacokinetic Study to Assess Drug-drug Interaction Between Zanubrutinib and a Cocktail of Substrates in Healthy Subjects

Status:
Completed

Trial end date:
2018-07-02

Target enrollment:

Participant gender:

Summary

This study is designed to evaluate the safety and pharmacokinetic interaction of effects of multiple doses of zanubrutinib with a "Cocktail" of five probe drugs for cytochrome P450 (CYP) 3A, CYP2C9, CYP2C19, P-glycoprotein and breast cancer resistance protein (BCRP) in healthy subjects

Phase:

Phase 1

Details

Lead Sponsor:

BeiGene

Treatments:

Zanubrutinib